NEW YORK (GenomeWeb News) – Perlegen Sciences intends to release its first diagnostic product, which is focused on stratifying risk and diagnosing breast cancer, during the first half of 2009, CEO Bryan Walser said on Thursday at the UBS Global Life Sciences Conference here.
 
The panel will contain eight single nucleotide polymorphisms, five of which are exclusive to Perlegen. The firm believes that its panel will have utility in both risk stratification as well as helping to guide treatment selection after diagnosis.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.